Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lapatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 0.99 |
| ▸ | ERBB2 known ✓ | P04626 | 17/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.87 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.87 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.87 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.87 |
| ▸ | STK10 | O94804 | 1/20 | 0.87 |
| ▸ | ABL1 | P00519 | 1/20 | 0.87 |
| ▸ | INSR | P06213 | 1/20 | 0.87 |
| ▸ | RET | P07949 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.87 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.87 |
| ▸ | SRC | P12931 | 1/20 | 0.87 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.87 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.87 |
| ▸ | CDK2 | P24941 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapatinib SCHEMBL31732815 | 1.00 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL93590 | 1.00 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL29866632 | 1.00 | ABCB11 (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL4926017 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL29356338 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL15408126 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL4097293 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL30680457 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL571898 | 0.99 | EGFR (1.00) | ABCB11EGFRERBB2MEN1PIK3C2B | |
| Lapatinib SCHEMBL29251597 | 0.95 | ABCB11 (0.91) | ABCB11EGFRERBB2MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117288869-B | Method for detecting p-toluenesulfonate impurities in bulk drug | 中国医学科学院医药生物技术研究所 | 2024-02-09 | — | — | CN | claimed |
| CN-113336851-B | Novel fully human anti-human B7H3 antibody, composition containing same and application thereof | 徐州医科大学 | 2021-12-24 | — | — | CN | claimed |
| CN-113827596-A | Application of lapatinib and/or pharmaceutically acceptable derivatives thereof in preparation of anti-enterovirus drugs | 武汉市金银潭医院(武汉市传染病医院) | 2021-12-24 | — | — | CN | claimed |
| CN-113336851-A | Novel fully human anti-human B7H3 antibody, composition containing same and application thereof | 徐州医科大学 | 2021-09-03 | — | — | CN | claimed |
| CN-110801434-A | Method for preparing lapatinib tosylate solid dispersion by freeze-drying method | 金华职业技术学院 | 2020-02-18 | — | — | CN | claimed |
| CN-120092017-A | Chimeric antigen receptor domains | 提克瓦阿洛塞尔私人有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-119816897-A | Multiple study assessment | 普罗科技有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119413943-A | High performance liquid chromatography method for simultaneously detecting methyl p-toluenesulfonate and ethyl p-toluenesulfonate in Wu Pati-Ni bulk drug | 山东齐都药业有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-12109232-B2 | Radiation/chemotherapy sensitizer to be used for intratumoral local injection and for controlled release of hydrogen peroxide with hydrogel as carrier | KORTUC INC. (JP) | 2024-10-08 | — | — | US | disclosed |
| EP-3574906-B1 | SOLID PREPARATION COMPRISING QUINAZOLINE DERIVATIVE | SHIONOGI & CO (JP) | 2024-07-03 | — | — | EP | disclosed |
| CN-117288869-B | Method for detecting p-toluenesulfonate impurities in bulk drug | 中国医学科学院医药生物技术研究所 | 2024-02-09 | — | — | CN | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20130005971-A1 | Process and Intermediates for Preparing Lapatinib | SCINOPHARM TAIWAN, LTD. (TW) | 2013-01-03 | — | — | US | disclosed |
| WO-2012083440-A1 | A PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS DITOSYLATE SALT | APOTEX PHARMACHEM INC (CA) | 2012-06-28 | — | — | WO | disclosed |
| US-20110288086-A1 | POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2011-11-24 | — | — | US | disclosed |
| US-20110097320-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | CONCERT PHARMACEUTICALS INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110053964-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | CONCERT PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| EP-2054063-A2 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Concert Pharmaceuticals Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080051422-A1 | 4-Aminoquinazoline derivatives and methods of use thereof | CONCERT PHARMACEUTICALS INC. (US) | 2008-02-28 | — | — | US | disclosed |
| WO-2008024439-A2 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | CONCERT PHARMACEUTICALS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005971-A1 | Process and Intermediates for Preparing Lapatinib | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ABCB11 738/4885 |
| US-20110288086-A1 | POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF | AURKA, AURKC, AURKB | EGFR 855/4885ERBB2 455/4885ABCB11 759/4885 |
| US-20110097320-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | ERBB2, ERBB4, EGFR | EGFR 3/4885ERBB2 1/4885ABCB11 232/4885 |
| US-20080051422-A1 | 4-Aminoquinazoline derivatives and methods of use thereof | ERBB2, ERBB4, EGFR | EGFR 3/4885ERBB2 1/4885ABCB11 232/4885 |
| US-20110053964-A1 | 4-AMINOQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | ERBB2, ERBB4, EGFR | EGFR 3/4885ERBB2 1/4885ABCB11 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.